Aadi Bioscience (AADI) Competitors $1.99 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AADI vs. MRKR, SYBX, ALLK, AKYA, CABA, ATAI, KOD, OGI, BIVI, and ADAPShould you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Marker Therapeutics (MRKR), Synlogic (SYBX), Allakos (ALLK), Akoya Biosciences (AKYA), Cabaletta Bio (CABA), Atai Life Sciences (ATAI), Kodiak Sciences (KOD), Organigram (OGI), BioVie (BIVI), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "medical" sector. Aadi Bioscience vs. Marker Therapeutics Synlogic Allakos Akoya Biosciences Cabaletta Bio Atai Life Sciences Kodiak Sciences Organigram BioVie Adaptimmune Therapeutics Aadi Bioscience (NASDAQ:AADI) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations. Which has more volatility & risk, AADI or MRKR? Aadi Bioscience has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Which has better earnings & valuation, AADI or MRKR? Marker Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAadi Bioscience$24.35M2.01-$65.76M-$2.42-0.82Marker Therapeutics$3.31M9.86-$8.24MN/AN/A Does the media prefer AADI or MRKR? In the previous week, Aadi Bioscience had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for Marker Therapeutics. Aadi Bioscience's average media sentiment score of 0.16 beat Marker Therapeutics' score of 0.00 indicating that Aadi Bioscience is being referred to more favorably in the media. Company Overall Sentiment Aadi Bioscience Neutral Marker Therapeutics Neutral Do analysts recommend AADI or MRKR? Aadi Bioscience currently has a consensus price target of $10.25, indicating a potential upside of 415.08%. Marker Therapeutics has a consensus price target of $19.00, indicating a potential upside of 419.13%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Aadi Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AADI or MRKR more profitable? Aadi Bioscience has a net margin of -274.77% compared to Marker Therapeutics' net margin of -278.27%. Aadi Bioscience's return on equity of -66.67% beat Marker Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aadi Bioscience-274.77% -66.67% -54.00% Marker Therapeutics -278.27%-78.91%-66.10% Does the MarketBeat Community prefer AADI or MRKR? Marker Therapeutics received 61 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 63.72% of users gave Marker Therapeutics an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote. CompanyUnderperformOutperformAadi BioscienceOutperform Votes1139.29% Underperform Votes1760.71% Marker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Do institutionals and insiders believe in AADI or MRKR? 52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 17.4% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryAadi Bioscience and Marker Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Aadi Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AADI vs. The Competition Export to ExcelMetricAadi BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.97M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.829.93114.8115.14Price / Sales2.01396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.465.324.665.02Net Income-$65.76M$153.56M$119.06M$225.46M7 Day Performance-1.00%0.13%0.80%0.37%1 Month Performance1.53%15.23%5.65%3.57%1 Year Performance-56.74%41.14%36.75%29.43% Aadi Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AADIAadi Bioscience4.2122 of 5 stars$1.99flat$10.25+415.1%-53.9%$48.97M$24.35M-0.8240Upcoming EarningsMRKRMarker Therapeutics3.5627 of 5 stars$4.21-2.5%$19.00+351.3%+28.9%$37.55M$3.31M0.0060Gap UpSYBXSynlogic2.7991 of 5 stars$1.42-0.7%$30.00+2,012.7%-16.6%$16.61M$3.37M-0.2180News CoverageALLKAllakos4.7608 of 5 stars$1.33+1.5%$1.67+25.4%-33.2%$117.70MN/A-0.57131Positive NewsGap UpAKYAAkoya Biosciences3.2976 of 5 stars$3.00+7.1%$6.56+118.8%-19.9%$148.16M$93.22M-2.4490Short Interest ↓Positive NewsCABACabaletta Bio2.4755 of 5 stars$4.15+6.1%$28.10+577.1%-74.8%$200.35MN/A-2.1850ATAIAtai Life Sciences2.0102 of 5 stars$1.19+4.4%$10.50+782.4%-9.2%$199.21M$378,000.00-2.9783Positive NewsKODKodiak Sciences4.5694 of 5 stars$3.77+0.8%$5.00+32.6%+149.4%$198.06MN/A-1.0090Positive NewsOGIOrganigram0.6422 of 5 stars$1.89+2.4%N/A+68.0%$196.51M$161.08M-4.51860Positive NewsBIVIBioVie2.5741 of 5 stars$3.15+10.1%$4.00+27.0%-39.8%$192.67MN/A-0.2310ADAPAdaptimmune Therapeutics2.9169 of 5 stars$0.76+3.1%$3.38+345.2%+48.1%$187.59M$141.46M-2.17449Short Interest ↓News Coverage Related Companies and Tools Related Companies MRKR Competitors SYBX Competitors ALLK Competitors AKYA Competitors CABA Competitors ATAI Competitors KOD Competitors OGI Competitors BIVI Competitors ADAP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AADI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
